Park Ha Biological Technology is trading 10.62% higher at $2.50 in pre-market; no fresh company-specific announcement explaining the November 5 move has appeared in available coverage.
- Yahoo Finance’s listed company headlines were older.
- Biotech-sector strength may be contributing: supplied sector context shows XBI up 2.08% pre-market, alongside a rally linked to Amgen’s results and improved guidance.
- The move follows a strong November 4 session; no company-specific catalyst has been identified.